CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 70 enrolled
Drug / intervention
Pioglitazonedrug
Likely dose
Pioglitazone 30mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00579813
NCT00579813Phase 4Completed
CompareCT.gov

Mechanisms Underlying Metabolic Syndrome in Obesity

Philip Kern·interventional·Posted Dec 24, 2007·Updated Jun 15, 2017

In Brief

A Phase 4 clinical trial evaluating Pioglitazone for Metabolic Syndrome and 2 related conditions. Completed, enrolled 70 participants across 2 sites.

Detailed Summary

The purpose of this study is to better understand the link between obesity and diabetes or pre-diabetes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetabolic Syndrome, Insulin Resistance, Prediabetes
CountriesUnited States
CollaboratorsNational Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Timeline

Phase 4CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 24, 2007
Enrollment StartApr 1, 2005
Primary CompletionJan 1, 2009
Study CompletionJan 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 18.5 years ago

Interventions

Pioglitazonedrug

Pioglitazone 30mg for 2 weeks, then Pioglitazone 45mg for 8 weeks.